Table 1.
Clinical data of SMA and Control Subjects.
Table 2.
Correlations of secondary measures with MHFMS and age for SMA subjects.
Table 3.
Results from primary outcome analysis across all seven “omic” platforms.
Figure 1.
Illustration of the top 5 markers as candidate biomarkers by age.
The natural log intensity of the protein abundance of CILP2, TNXB, COMP, ADAMTSL4 and CLEC3B are shown by age (Panels A-E) across Types. Panels A-E generally show a trend for type but not age.
Figure 2.
Illustration of the top 5 markers as candidate biomarkers by MFMHS.
The natural log intensity of the protein abundance of CILP2, TNXB, COMP, ADAMTSL4 and CLEC3B are shown by MHFMS (Panels A-E) across Types. Panels A-E again show a trend for type and MHFMS. Panels F-J shows the box plot distribution by type.
Figure 3.
Illustration of the top 5 markers as candidate biomarkers by Type.
The natural log intensity of the protein abundance of CILP2, TNXB, COMP, ADAMTSL4 and CLEC3B are shown (Panels A-E) by Type. Error bars are expressed as standard errors.
Table 4.
Top 20 univariate MHFMS markers across platforms.
Table 5.
Top 20 univariate markers across all outcome measures.